• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Unproven Treatments

Background

Because there is no cure for ALS/MND, and approved treatments have a limited effect, people diagnosed with the disease may seek out options that are not offered by their physician. Determining the difference between true and false information regarding ALS treatments can be difficult.

The internet has many websites that promote effective ALS treatments for purchase. Often they are well designed, boast treatments available for multiple diseases and ailments, and provide reassurance through online testimonials from previous clients. In nearly all of these cases, there is no evidence of safety, and in none has a benefit been shown in rigorous scientific studies. Furthermore, these treatments are often extremely expensive, and they are marketed to people who are looking for options. Many people with ALS spend critical life savings or raise funds through family and friends for an opportunity to save their life.

Unproven treatments are sometimes called alternative or off-label treatments. Examples include, but are not limited to: stem cell clinics; holistic, naturopathic, homeopathic, and traditional medicine; and dietary or physical therapy regimens.

Resources like ALSUntangled can be valuable for balanced, open-access information about such alternative treatments, and ClinicalTrials.gov is a resource for determining whether a particular treatment is being tested in a legitimate clinical trial.

The ALSUntangled article “Ten red flags”—things to be wary of in alternative or off-label products—provides a helpful guide to the warning signs to look out for in an advertised potential treatment. Read the “Ten red flags” article.

Recommendation

The SAC recommends that Alliance members defer all medical advice regarding unapproved, unproven, or off-label treatments to an individual’s own clinician. This may be accompanied by objective information about the specific treatment, which may be provided by the SAC. Providing links to resources like ALSUntangled and clinical trials databases like ClinicalTrials.gov is encouraged. Accompanying information can be especially important in situations where an individual does not have access to an ALS specialist physician, and it may assist their clinician in making a medical recommendation. It can also be important to relay that there are thousands of researchers around the world who are dedicated to understanding ALS and finding effective treatments, and if there were anything, anywhere, that actually worked, we would know and we would do everything we could to get it to people living with the disease as soon as possible.

International Alliance of ALS/MND Associations
June 2020


The original language of communication is English, and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Ian Gale, Australia

    Ian Gale, Australia

  • Steve Gallagher, Canada

    Steve Gallagher, Canada
    Picture1

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Peng Yi-Wen, Taiwan

    Peng Yi-Wen, Taiwan

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • John Sweeney, USA

    John Sweeney, USA

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Maria Lucia Wood Saldanha, Brazil

    Maria Lucia Wood Saldanha, Brazil

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Daniela Maria Daverio, Argentina

    Daniela Maria Daverio, Argentina

  • Michael Lee, Australia

    Michael Lee, Australia

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • JP

    JP

  • Mary Thomas, Australia

    Mary Thomas, Australia

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Marcelo Farinelli, Brazil

    Marcelo Farinelli, Brazil

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Dick Dayton, USA

    Dick Dayton, USA

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Andrietta, Italy

    Andrietta, Italy
    Andrietta

  • Andrea Zicchieri, Italy

    Andrea Zicchieri, Italy
    AndreaZicchieri_conSLAncioItaly

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Magdalena Ayala Rodríguez, Mexico

    Magdalena Ayala Rodríguez, Mexico

  • Alex, Argentina

    Alex, Argentina

  • Yolanda Armendariz, Mexico

    Yolanda Armendariz, Mexico

  • Mark Miller, UK

    Mark Miller, UK

  • Philip Brindle, England

    Philip Brindle, England

  • Juvenal Bayona Romero, Colombia

    Juvenal Bayona Romero, Colombia

  • Inta Grubb, Australia

    Inta Grubb, Australia

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • David Hall, USA

    David Hall, USA

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • David Solomon, UK

    David Solomon, UK

  • Karl Hughes, Ireland

    Karl Hughes, Ireland

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Chih Ching Darren Wong, Malaysia

    Chih Ching Darren Wong, Malaysia

  • Richard Clark, New Zealand

    Richard Clark, New Zealand

  • Art Eggert, USA

    Art Eggert, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login